Andrew D. Zelenetz

Also affiliated with Cornell University, Presbyterian Hospital

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 35 papers. Top paper: “Outcomes of COVID-19 in patients with CLL: a multicenter international experience”.

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Blood(2020)10.1182/blood.2020006965

N/A

13.4DataRank · unranked

318 citations

Lindsey E. Roeker, Nicole Lamanna, John N. Allan, Lori A. Leslie, John M. Pagel +57 more

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

Blood(2020)10.1182/blood.2019003277

N/A

3.7DataRank · unranked

95 citations

Mei‐Yin C. Polley, Michael V. Knopp, Nathan C. Hall, Lale Kostakoglu, Jun Zhang +14 more

Positron-emission tomography–based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma

European Journal of Cancer(2020)10.1016/j.ejca.2019.12.006

N/A

1.3DataRank · unranked

29 citations

Fushen Sha, Anna Alperovich, Ai Ni, Katy Smith, Zhitao Ying +20 more

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Blood(2022)10.1182/blood.2022015851

N/A

1.1DataRank · unranked

1538 citations

Elaine S. Jaffe, James R. Cook, Leticia Quintanilla‐Martínez, Steven H. Swerdlow, Kenneth C. Anderson +68 more

Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2183

N/A

0.850DataRank · unranked

22 citations

Laure Michaud, Karissa Whiting, Reiko Nakajima, Chelsea Nichols, Stephanie De Frank +19 more

Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

Blood Cancer Journal(2020)10.1038/s41408-020-00340-z

N/A

0.798DataRank · unranked

204 citations

Fushen Sha, Anna Alperovich, Ai Ni, Katy Smith, Zhitao Ying +20 more

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia

Leukemia(2020)10.1038/s41375-020-01030-2

N/A

0.705DataRank · unranked

109 citations

David A. Knorr, Melissa S. Pessin, Lakshmi V. Ramanathan, Meghan C. Thompson, Lori A. Leslie +3 more

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

Blood Advances(2020)10.1182/bloodadvances.2020001956

N/A

0.673DataRank · unranked

88 citations

Peter Dreger, Jennifer R. Brown, Oscar Lahoud, Toby A. Eyre, Danielle M. Brander +20 more

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

Blood(2025)10.1182/blood.2024025563

N/A

0.596DataRank · unranked

52 citations

Jacob Soumerai, Jeremy S. Abramson, Jeffrey A. Barnes, Philip Caron, Shalini Chhabra +23 more

TP53mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy

Blood Advances(2023)10.1182/bloodadvances.2023009953

N/A

0.505DataRank · unranked

28 citations

Nivetha Ganesan, Zachary D. Epstein‐Peterson, Alison J. Moskowitz, Robert Stuver, Catherine Maccaro +27 more

Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma

Blood Cancer Journal(2022)10.1038/s41408-022-00620-w

N/A

0.291DataRank · unranked

5 citations

Michelle Okwali, Anna Alperovich, Philip Caron, Lorenzo Falchi, Audrey Hamilton +22 more

Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop

Blood Advances(2025)10.1182/bloodadvances.2025018079

N/A

0.208DataRank · unranked

3 citations

Sarah C. Rutherford, Stephen M. Ansell, Philippe Armand, John P. Leonard, Loretta J. Nastoupil +20 more

Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes

Blood Cancer Journal(2024)10.1038/s41408-024-01148-x

N/A

0.208DataRank · unranked

3 citations

Efrat Luttwak, Alfredo Rivas‐Delgado, Helen Irawan, Alexander P. Boardman, Philip Caron +26 more

Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma

Blood Advances(2025)10.1182/bloodadvances.2024014263

N/A

0.113DataRank · unranked

1 citations

Parastoo B. Dahi, Farhad Khimani, Andrei R. Shustov, Mazyar Shadman, Jia Ruan +19 more

Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma

Haematologica(2025)10.3324/haematol.2024.286813

N/A

0.104DataRank · unranked

1 citations

Manik Uppal, Serena Zheng, Kurt S. Bantilan, Connie Lee Batlevi, Zachary D. Epstein‐Peterson +21 more

Long‐term outcomes of patients with limited‐stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era

British Journal of Haematology(2022)10.1111/bjh.18590

N/A

0DataRank · unranked

2 citations

Brandon S. Imber, Michelle Okwali, Paul A. Hamlin, Anita Kumar, Oscar Lahoud +11 more

Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma

British Journal of Haematology(2023)10.1111/bjh.19178

N/A

0DataRank · unranked

7 citations

Ariela Noy, Santosha A. Vardhana, Andrew D. Zelenetz, Alison J. Moskowitz, Robert Stuver

Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study

Leukemia & lymphoma/Leukemia and lymphoma(2023)10.1080/10428194.2022.2164194

N/A

0DataRank · unranked

9 citations

Ariela Noy, David J. Straus, Matthew J. Matasar, Craig H. Moskowitz, Venkatraman Seshan +6 more

Retrospective characterization of nodal marginal zone lymphoma

Blood Advances(2023)10.1182/bloodadvances.2022009587

N/A

0DataRank · unranked

8 citations

Esther Drill, David Qualls, Michelle Okwali, Connie Lee Batlevi, Philip Caron +24 more

Data from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring

(2023)10.1158/1078-0432.c.6530889.v1

N/A

0DataRank · unranked

0 citations

Laure Michaud, Karissa Whiting, Reiko Nakajima, Chelsea Nichols, Stephanie De Frank +19 more

Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

(2023)10.1158/1078-0432.c.6532596

N/A

0DataRank · unranked

0 citations

Tatyana Feldman, Jacob D. Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey +21 more

Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

(2023)10.1158/1078-0432.c.6532596.v1

N/A

0DataRank · unranked

0 citations

Tatyana Feldman, Jacob D. Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey +21 more

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Science(2024)10.1126/science.adi5798

N/A

0DataRank · unranked

152 citations

Jessie Bourcier, Mark Noviski, Hao Lu, Meghan C. Thompson, Alexandra Chirino +48 more

Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas

British Journal of Haematology(2024)10.1111/bjh.19419

N/A

0DataRank · unranked

5 citations

Catherine Diefenbach, Deepa Jagadeesh, Adam Asch, Abhijeet Kumar, Michaela L. Tsai +11 more

Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma

Leukemia & lymphoma/Leukemia and lymphoma(2024)10.1080/10428194.2024.2430703

N/A

0DataRank · unranked

1 citations

Martina Pennisi, Miguel‐Angel Perales, Gunjan L. Shah, Andrew D. Zelenetz, Joachim Yahalom +4 more

CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas

Blood Neoplasia(2024)10.1016/j.bneo.2024.100031

N/A

0DataRank · unranked

1 citations

Kurt S. Bantilan, Erel Joffe, M. Lia Palomba, Ariela Noy, Philip Caron +12 more

120 | DETECTION OF INTRATUMORAL MICROORGANISMS AND THEIR IMPACT ON OUTCOMES IN UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA

Hematological Oncology(2025)10.1002/hon.70093_120

N/A

0DataRank · unranked

0 citations

Chad Vanderbilt, Teng Fei, Ticiane Henriques Santa Rita, A. Rivas Delgado, Annie Qiu +31 more

Comparative DNA Methylation Profiling of Human and Murine ALK‐Positive B‐Cell Neoplasms

Genes Chromosomes and Cancer(2025)10.1002/gcc.70060

N/A

0DataRank · unranked

0 citations

Rabea Wagener, Shannon Harkins, Claudia Voena, Susanne Bens, Wolfram Klapper +13 more

Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?

Blood Advances(2021)10.1182/bloodadvances.2021004939

N/A

0DataRank · unranked

42 citations

Karen Chau, Jasme Lee, Jisun Lee, Dana L. Casey, Joanna C. Yang +13 more

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3815

N/A

0DataRank · unranked

116 citations

Lindsey E. Roeker, Ryan Jacobs, Brian T. Hill, Nicole Lamanna, Danielle M. Brander +49 more

Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter’s transformation

Blood Advances(2021)10.1182/bloodadvances.2020003726

N/A

0DataRank · unranked

30 citations

Sean M. Devlin, Molly Maloy, Lindsey E. Roeker, Parastoo B. Dahi, Doris M. Ponce +13 more

Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma

UNC Libraries(2020)10.17615/e2t6-bj50

N/A

0DataRank · unranked

0 citations

Marco Rais, Tongzhang Zheng, Lesley F. Tinker, Anne Tjønneland, Brenda M. Birmann +27 more

Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy (PN) in patients with diffuse large B-cell lymphoma on CALGB 50303 (Alliance).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e13535

N/A

0DataRank · unranked

0 citations

Nicholas B. Larson, Timothy M. Pierpont, Nancy L. Bartlett, Andrew D. Zelenetz, Wyndham H. Wilson +5 more

Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0964

N/A

0DataRank · unranked

13 citations

Tatyana Feldman, Jacob D. Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey +21 more

Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection

Leukemia & lymphoma/Leukemia and lymphoma(2022)10.1080/10428194.2022.2148218

N/A

0DataRank · unranked

4 citations

Neil E. Kay, Sameer A. Parikh, Kari G. Rabe, Timothy G. Call, José F. Leis +7 more